Business context and reporting period
Entity mismatch: The request identifies Vivosim Labs, Inc., but the supplied Form 10-Q is for Organovo Holdings, Inc. Verify that this is the intended filing. The report covers the quarter and nine months ended December 31, 2017; the quarter is fiscal Q3 for the year ending March 31, 2018.
Organovo develops and commercializes bioprinted living-tissue products and services for research and drug development, and is advancing therapeutic tissue programs focused on liver disease. Its lead therapeutic program targets Alpha-1 antitrypsin deficiency.
Financial performance and position
Amounts below are in millions of dollars, except per-share data and percentages. The interim statements are unaudited.
| Metric | Three months ended Dec. 31, 2017 | Prior-year quarter | Nine months ended Dec. 31, 2017 | Prior-year nine months |
|---|---|---|---|---|
| Revenue | $1.153 | $1.151 | $3.498 | $3.418 |
| Gross profit (gross margin) | $0.961 (83.3%) | $0.939 (81.6%) | $2.751 (78.6%) | $2.645 (77.4%) |
| Operating loss | $(7.909) | $(9.631) | $(27.688) | $(27.887) |
| Net loss | $(7.791) | $(9.581) | $(27.354) | $(27.790) |
| Net loss per share, basic and diluted | $(0.07) | $(0.09) | $(0.26) | $(0.29) |
At December 31, 2017, cash and cash equivalents were $47.338 million, versus $62.751 million at March 31, 2017. Working capital was $46.0 million, down from $59.1 million. Total assets were $53.554 million and total liabilities were $4.953 million. The balance sheet does not show a material borrowings balance; liabilities principally include accounts payable, accruals, deferred revenue, and deferred rent.
For the nine months, operating cash use was $23.246 million (prior year: $21.959 million); investing cash use was $0.160 million (prior year: $1.109 million); and financing provided $7.995 million (prior year: $30.983 million). Cash declined by $15.413 million. Financing included $7.1 million of net ATM proceeds and approximately $0.9 million from option exercises and employee stock purchases.
Changes versus prior comparable periods
- Quarterly revenue was essentially flat. Product and service revenue rose 19% in the quarter and 14% for the nine-month period, supported by liver disease-modeling services and human cell and tissue products. Lower collaboration and license revenue partly offset that growth.
- Nine-month total revenue increased 2%. Grant revenue increased following commencement of the NIH-funded work; the company reported $0.260 million for the quarter and $0.409 million for the nine months.
- Quarterly operating loss narrowed by $1.722 million, mainly as R&D and SG&A expenses declined. Nine-month operating loss was broadly unchanged.
- Nine-month operating cash use increased by $1.287 million, which management attributed primarily to a $2.5 million increase in working capital, partly offset by lower cash operating expenses.
- Outstanding common shares rose from 104.6 million at March 31 to 109.3 million at December 31. The company also issued 1.5 million shares through its ATM in January 2018 for net proceeds exceeding $2.1 million.
Outlook, risks, contingencies, and notable items
- Management said existing cash and its current operating plan were sufficient to fund operations for at least 12 months from the financial statement issuance date. It also said additional capital will be needed to further develop and commercialize its platform and therapeutic programs.
- The company expected to file its first IND for the Alpha-1 antitrypsin deficiency program by the end of calendar 2020. The FDA granted the program orphan drug designation in December 2017.
- Management warned that future financing may not be available on acceptable terms. Equity financing could dilute shareholders; debt financing could add payment obligations and restrictive covenants. Insufficient capital could force program delays, reductions, or discontinuation.
- Restructuring affected expenses and staffing: average quarterly R&D headcount declined to 65 from 78 a year earlier. Nine-month SG&A included $0.8 million of restructuring-related severance costs.
- Related-party arrangements included $94,000 of nine-month services revenue from Cirius Tx, whose CEO was a company director, and $323,000 of revenue recognized under a collaboration with Viscient Biosciences, led by a former Organovo director and CEO.
- The company disclosed operating lease commitments of $4.497 million. It reported no legal accrual and no contingency loss it considered probable or reasonably estimable, while noting legal outcomes remain uncertain.
- The company was evaluating the impact of the December 2017 Tax Cuts and Jobs Act and recorded no provisional tax effects. It anticipated a minimal net tax-provision effect after the valuation allowance, subject to further analysis.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Organovo Holdings, Inc., not Vivosim Labs, Inc.
- Assess whether the stated 12-month funding horizon remains adequate in light of the $23.2 million nine-month operating cash use and management’s expectation of needing additional capital.
- Review revenue mix and durability, including growth in products and services, declining collaboration revenue, and milestone-based NIH grant revenue.
- Evaluate dilution and financing capacity, including ATM issuance, the January 2018 share sale, and outstanding equity awards and reserved shares.
- Track progress toward the targeted 2020 IND filing and the development, regulatory, and commercial risks of the therapeutic programs.